CYP3A4 and tuberculosis: We report here the results using two broad categories of medications evaluated for potential drug-drug interactions in the delamanid development program: first-line anti-TB drugs (including the strong CYP3A4 and other CYP450 isoenzymes inducer rifampin) and antiretroviral drugs used in HIV-infected patients (including the moderate CYP3A4 inducer efavirenz) and the strong CYP3A4 inhibitor ritonavir.